Please login to the form below

RWE Blog 2: Payers use real-world data cautiously

Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.

While companies and regulators are becoming increasingly enthusiastic about RWD and RWE, payers remain cautious. They’re using concerns regarding real-world therapeutic value as an argument to draw conclusions on what they deem as ‘unquantifiable benefit’ at the time of market entry.

There are practical and ethical barriers to using drugs in the real world before full regulatory approval:

  • Practical: product availability and distribution, follow-up of patients
  • Ethical: use in patients before definite proof of therapeutic value

These barriers do make it difficult to overcome arguments against real-world use, potentially leading to restricted reimbursement until generated RWD become available. Conditional reimbursement – reimbursement pending positive RWE in the future – is a potential solution, but isn’t yet widely implemented.

The RWE argument is a slow build

There is growing support for using RWD and RWE in decisions around reimbursement, coverage, pricing and payment, but the take-up by payers is lagging well behind.

A 2017 review of the use of RWE in 27 pharmacy and therapeutic (P&T) committee monographs and therapeutic class reviews, from six different payer organisations, found 21 references that published RWE, versus 155 that published randomised controlled trials (RCTs) in therapeutic class reviews. There were no references to published RWE in the monographs. The authors concluded that efficacy information, such as clinical trials and product labels, were the most cited pieces of evidence in P&T materials. Effectiveness information, even among therapeutic class reviews where RWE is more available, were still only used infrequently.

There are slight moves forward, however. The ISPOR Real-World Data Task Force Report describes the use of RWD in RCTs as the gold standard for demonstrating clinical efficacy, and recognises that RWD can contribute to the evidence base needed for coverage and payment decisions.

According to a report from the 2017 ICER Membership Policy Summit, both health technology assessment (HTA) organisations and payers rely largely on evidence from controlled trials, particularly that generated for regulatory submissions, for initial HTA assessments and payer coverage decisions. The bodies use RWE for re‑assessments such as safety signals, adherence, effectiveness and value for money, and effectiveness within sub-populations, as well as in outcomes-based contracting.

France is taking effectiveness on board

The French Transparency Commission uses considerations about effectiveness as one of the elements in its reimbursement decision-making process. Real-world related concerns regarding application of new therapies based only on RCTs, taken from French appraisal documents, include:

  • uncertainties about the criteria to identify the population of patients most likely to benefit from the product in clinical practice
  • age and risk distribution of selected patients, dose of comparator, and additional measures, are not in line with daily practice
  • only few patients were pre-treated with the standard of care normally used in the previous line
  • it’s unlikely the complicated therapeutic strategy would work in daily practice
  • the proposed treatment hasn’t been studied on top of the current normal educational and psychological treatment
  • the product hasn’t been studied in the normal combination
  • selected patients didn’t include the frail ones, so the benefit/risk ratio could be very different

Looking at effectiveness in the UK

In the UK, the National Institute for Health and Care Excellence (NICE) uses HTA in funding decisions, and an important part of the assessment is about clinical effectiveness. However, although the NICE guidelines state that the appraisal committee’s judgements on clinical effectiveness must take account of “uncertainty generated by the evidence and differences between the evidence submitted for licensing and that relating to effectiveness in clinical practice”, they also highlight the importance of “evidence derived from high-quality studies with methodology designed to minimise bias”.

Effectiveness and the funding of drugs in Poland

RWE is used extensively in the decision-making processes involving public funding of drugs in Poland, contributing to 45% of all evidence considered. However, it’s important to point out that – according to the latest Patients W.A.I.T. (Patients Waiting to Access Innovative Therapies) publication – the average time between marketing authorisation and patient access is 612 days for Poland, compared with 209 for the UK. This shows more opportunity to generate RWD in Poland.

The biggest role for RWD and RWE for payers is currently in re-assessments, or for late market entries. As regulators show more confidence in RWE, and as companies become better at developing real-world-type studies, its use for payers may become more applicable for funding decisions.

To read about the payers’ use of RWE in more depth, download our white paper Real-world evidence: Hurdles and the holy grail.

Ready to use real-world evidence to its full potential to improve market access to your product? Call us on: +44 (0) 20 3750 9833 or email us at: discover@validinsight.com.

5th November 2019

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
Using TRAVELLESS™ to provide tailored pharmaceutical training
In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
The vicious circle of pharmaceutical tendering
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
The benefits of a expert-led market access strategy
In order to support effective decision making and deliver sustained returns in a complex, dynamic healthcare environment, pharmaceutical, biotech and medical device companies need an expert-led market access strategy that considers the changing nature of the real-life marketplace. These strategies should not only focus on achieving the commercial objectives for a product but also enable it to outperform competitors throughout the product life cycle.
Valid Insight